

The 3rd University of Würzburg  
Anti-Counterfeit Conference

# Strategies against Falsified/ Counterfeit Medicines

How to Establish Anti-Counterfeit  
Strategies in Pharmaceutical  
Companies

7 - 8 May 2012

Würzburg (near Frankfurt), Germany

**SPEAKERS:**

**Dr Hans-Joachim Bigalke**  
*EDQM, France*

**Dr Thomas Hecker**  
*EDQM, France*

**Prof Dr Ulrike Holzgrabe**  
*University of Würzburg, Germany*

**Andreas Maack**  
*Merck KGaA, Germany*

**Dieter Mößner**  
*Carl Edelman GmbH, Germany*

**Dr Stephan Schwarze**  
*Bayer Pharma AG, Germany*

**Dr Bernd Renger**  
*European QP Association, Germany*

**Dr Mona Tawab**  
*ZL, Germany*

**Dr Hermann Thöne**  
*Novartis Pharma AG, Switzerland*

**Dr Christian Tillmanns**  
*Meisterernst Rechtsanwälte, Germany*

**Dr S. Leigh Verbois**  
*CDER, FDA, USA (via Video Conference)*

**HIGHLIGHTS:**

- Regulatory Updates:
  - EU Directive on Falsified Medicines – Update and Consequences
  - The Revised EU Good Distribution Practice Guide – Expectations and Concerns
- Setting up, Implementing and Running a Successful Global Anti-counterfeiting Program
- Authentication of Suspect Samples: Recent Examples of Counterfeit Medicines
- Counterfeit Drugs in Europe: Status Quo and Options to Identify them
- Focusing on Falsification/Manipulation during GMP Inspections
- Case Studies for Coding and Track&Trace:
  - EDQM Anti-Counterfeiting Traceability Service for Medicines (eTact)
  - “securPharm” – German Stakeholder Initiative to Avoid Falsified Medicine Reaching Patients
  - The Mobile Authentication Service (MAS)
- Coding / Track & Trace Requirements Worldwide
- Tamper Verification Features for Medicinal Product Packaging
- FDA's Anti-Counterfeit Strategies – Update and Future Activities

Exclusive Media Partner:



Dear Colleagues,



It is a great pleasure for me to invite you to the 3rd International Conference "Strategies against Falsified / Counterfeit Medicines" in Würzburg. After two successful conferences in November 2008 and April 2010, this is the third conference on this topic, again supported by the University of Würzburg.

Counterfeit APIs and medicines pose a growing threat to patients worldwide, with increasing numbers in Europe and the USA. Customs all over the world find more and more illegally produced drugs. Moreover, drugs are increasingly sold via the Internet making it much easier to put counterfeits into circulation.

Thus, strategies against counterfeited medicines become more important. With this in mind, our new conference programme will focus on:

- The new Falsified Medicine Directive and the revised EU Good Distribution Practice Guide
- Case studies for anti-counterfeiting strategies in pharmaceutical companies
- The new tamper verification feature initiative
- Actual track&trace (T&T) developments in Europe ("securPharm", EDQM's eTACT) and coding and T&T requirements worldwide
- FDA's anti-counterfeit strategies and current activities

The aim of this event is to provide a platform for interesting and interactive discussions with regulatory authority representatives, industry experts, university colleagues and delegates from suppliers of anti-counterfeiting products and systems to exchange experiences on the various aspects of anti-counterfeiting activities.

It will be a great pleasure for me to welcome you in Würzburg on behalf of the Institute of Pharmacy and Food Chemistry of our University.

Prof Dr Ulrike Holzgrabe  
Chair of Pharmaceutical and Medicinal Chemistry  
University of Würzburg

### The University of Würzburg

With over 600 years of tradition, the Julius Maximilian University of Würzburg is today one of Germany's mid-sized universities. 400 professors in 10 faculties here teach roughly 24,000 students. The University of Würzburg is among the leading institutions of higher education in Germany; this has been confirmed by rankings carried out by national and international research organizations, international external assessment committees as well as by the German Federal and State Excellence Initiatives (founded in 2006). Internationally, the University of Würzburg is also one of the top-ranking academic institutions in many fields of research and study.

### The German Pharmaceutical Society (Deutsche Pharmazeutische Gesellschaft)

The German Pharmaceutical Society (DPHG), founded in 1890 in Berlin, is one of the oldest German scientific societies (10,000 members). The aims of the DPhG are to promote the pharmaceutical sciences and interdisciplinary way of thinking, to encourage junior scientists within the pharmaceutical community, to maintain contact with foreign scientists and with foreign special societies, to facilitate transfer of new scientific knowledge into pharmacy practice, to advise legislative and administrative bodies on pharmaceutical matters and to establish position statements on pharmaceutical questions of public interest.

### The European QP Association

The European Qualified Person (QP) Association was founded in July 2006 by the European Compliance Academy's (ECA) Advisory Board Members. The European Qualified QP Association wants to provide QPs in Europe with a platform allowing them to exchange their experience, discuss the latest regulatory requirements, to identify and address difficulties and challenges and to support a harmonised European approach.

<http://www.qp-association.eu/>

### Media Partner

---

### Pharmaceutical anti-counterfeiting news from SecuringPharma.com.

SecuringPharma.com is a free-to-access information service that covers the issues surrounding supply chain and brand security in the pharmaceutical industry. Our aim is to provide practical advice and intelligence to help manufacturers define and pursue their own strategies for tackling pharmaceutical crime including counterfeiting, diversion and theft. We cover key developments in:

- authentication, verification and track-and-trace technologies
- the regulatory environment;
- issues relating to corporate liability;
- the evolution of data standards;
- drug pedigrees;
- legal options to tackle the counterfeiters; and much more.

The site incorporates breaking news and features, researched and written by specialist industry journalists and guest writers, as well as a regularly updated feed of external editorial from the world's press, a comprehensive and intuitive directory of security-related goods, technologies and services, plus the latest market research and events in the pharmaceutical supply chain arena. Our editorial mission is to identify the most important and relevant information in pharmaceutical brand protection and bring it into one place for our community of readers. Website: [www.SecuringPharma.com](http://www.SecuringPharma.com)

# Strategies against Falsified/Counterfeit Medicines

7 - 8 May 2012, Würzburg, Germany

## Objectives

---

The aim of this conference is to present both the regulatory authorities' activities and the pharmaceutical industry's activities to develop and establish appropriate counterfeit protection systems. The conference will focus on effective and affordable strategies, improve collaboration among regulators and pharmaceutical industry, and discuss actions in the global fight against counterfeit.

## Background

---

According to the European Commission the risk that falsified medicines reach patients in the EU is growing every year. And also the EMA is aware of an increase in falsified medicines. Until recently, the most frequently falsified medicines in wealthy countries were expensive "lifestyle" medicines. Today, more and more medicines used to treat serious illness are now being falsified.

The EMA and the European Commission differentiate between falsified and counterfeit medicines. While **falsified medicines** are fake medicines that are designed to mimic real medicines including its ingredients, documentation and supply chain, **counterfeit medicines** are medicines that do not comply with intellectual-property rights or that infringe trademark law.

In July 2011 the European Union officially published the **Directive 2011/62/EU about the prevention of the entry into the legal supply chain of falsified medicinal products**. The aim of this Directive is to prevent falsified medicines entering the legal supply chain and reaching patients. This includes:

- an obligatory safety feature on the outer packaging of the medicines (such as a serialization number)
- an EU-wide logo to identify legal online pharmacies
- tougher rules on the controls and inspection procedures of APIs
- more stringent record-keeping requirements for wholesale distributors
- obligation of the manufacturing authorization holder to immediately inform on any suspected falsified medicinal product

The **Concept Paper** of the European Commission submitted for public consultation about the "Delegated Act in the Detailed Rules for a **Unique Identifier for Medicinal Products for Human Use, and its Verification**" was published in November 2011. Linear barcodes, 2D-Barcodes and RFID were proposed as potential data carrier to be assessed in this Concept Paper.

In Europe a mass serialization initiative was started by the European Directorate for the Quality of Medicines and HealthCare (**EDQM**), known as "**eTact**". In contrast there are also local initiatives like the German "securPharm" initiative which started in August 2011. It will be crucial to follow these developments and to see which systems will be used in the future.

Another important document in this context is the draft of the **revised EU Guideline on Good Distribution Practice** of Medicinal Products for Human Use. This Draft Guideline now also covers "falsified medicinal products". Very important is the fact that the national competent authority would have to be informed "without delay" about any complaint concerning a potential falsified product.

In addition, on October 28, 2011 twelve countries signed the **Medicrime Convention** on Counterfeit Medicines. This Convention will allow to re-enforce national legislations in terms of prevention, protection of victims of counterfeit medical products and prosecution of counterfeiters through dissuasive sanctions. This Convention will also boost international co-operation between competent health and law enforcement authorities.

And also in the US the "**Counterfeit Drug Penalty Enhancement Act**" is on its way, which will increase the maximum fines for both individuals and firms manufacturing or trafficking in counterfeit medicines.

The FDA Guideline for Industry "Incorporation of Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting" has been finalised in October 2011.

It is the aim of this conference to inform participants about the latest regulatory requirements in the EU and the US (including the Track& Trace Requirements of all important markets for the pharmaceutical industry) and the measures the pharmaceutical industry has to take to combat counterfeit medicines.

## Target Audience

---

This conference is intended for people working in

- Packaging Development
- R&D
- Manufacturing / Packaging
- Quality Assurance / Quality Control (QPs)
- Purchasing and Materials Management
- Regulatory Affairs
- Counterfeit Protection Management

of pharmaceutical, biopharmaceutical and API manufacturing companies.

The conference is also intended for members of national or international authorities and for personnel working in Security Technology, and Packaging Components or Labelling companies.

## Moderator

---

Prof Dr Ulrike Holzgrabe  
University of Würzburg, Germany

# Strategies against Falsified/Counterfeit Medicines

7-8 May 2012, Würzburg, Germany

## Programme

---

### Session 1

#### Introduction / Current Challenges

##### Introduction to the Conference

- Quality of APIs
- Heavy metals, residual solvents, dioxin, DEHP/DINP, and others?
- Does "Track and Trace" help?

*Prof Dr Ulrike Holzgrabe, University of Würzburg*

##### Counterfeit Drugs in Europe: Status Quo and Options to Identify them

- Statistical update
- Case studies of the ZL
- Options for identification in daily practice
- Technical possibilities

*Dr Mona Tawab, ZL, Germany*

### Session 2

#### New Regulation: EU Falsified Medicine Directive and GDP

##### EU Directive on Falsified Medicines – Update and Consequences

- Key measures of the Directive
- Obligations of manufacturers (finished products, APIs)
- "Delegated acts"
- Time line

*Dr Christian Tillmanns, Meisterernst Rechtsanwälte, München, Germany*

##### The Revised EU Good Distribution Practice Guide – Expectations and Concerns

- Modern complex distribution channels
- GDP – for distributors only?
- Quality systems and Risk management – new concepts or well established processes?
- How to balance new requirements and existing structures and processes
- Role and responsibility of the manufacturer's quality System

*Dr Bernd Renger, European QP Association, Germany*

### Session 3

#### Case Studies – Anticounterfeiting Strategies

##### Setting up, Implementing and Running a Successful Global Anticounterfeiting Program

- Patient safety, customer safety and the integrity of Merck pharmaceutical and chemical products in all markets is top priority for Merck
- Merck's commitment to provide unaltered products of the highest quality to patients and customers
- Merck's responsibility to identify and take action against criminal activities relating to Merck products

- Close cooperation with and support of governments, authorities, supranational bodies and associations as well as business partners
- In order to fight product crime, counterfeiters and illegal dealers, various departments at Merck are working together in the Merck Anti-Counterfeiting Operational Network (MACON), coordinated by Corporate Security

*Andreas Maack, Merck KGaA, Germany*

##### Authentication of Suspect Samples: Recent Examples of Counterfeit Medicines

- The authentication of suspect medicines samples, in order to determine whether they are genuine or counterfeit as necessary prerequisite for subsequent action
- Tools used for the authentication including plausibility checks of the variable batch data, visual inspection, checking of the presence of overt and covert security features and chemical testing
- Adequate action to be initiated once a counterfeit product was identified, up to and including seizures, removal of counterfeit product from the market and arresting of the perpetrators, if possible

*Dr Hermann Thöne, Novartis Pharma AG, Switzerland*

##### Focusing on Falsification/Manipulation during GMP Inspections

- Manipulation of Documents
- Shadow facilities
- Summary of Experience
- Tips and Soft Skills during Inspections/Audits

*Dr Thomas Hecker, EDQM, France*

### Session 4: Case Studies

#### Coding / Track&Trace and End-to-End Solutions

##### "securPharm" – German Stakeholder Initiative to Avoid Falsified Medicine Reaching Patients

- Idea and purpose
- Current Status
- Vision

*Dr Stephan Schwarze, Bayer Pharma AG, Germany*

##### eTACT, the EDQM Anti-Counterfeiting Traceability Service for Medicines

Current status of the project and the next steps, with a focus on

- flexibility by supporting centralised and de-centralised architectures,
- interoperability by using non-proprietary standards,
- the public governance model for the proposed service.

*Dr Hans-Joachim Bigalke, EDQM, France*

## Coding / Track & Trace Requirements Worldwide

- Overview on coding / T&T schemes in different countries
- Purpose and Implementation
- Corresponding regulations / legal provisions

*Dr Stephan Schwarze, Bayer Pharma AG, Germany*

## The Mobile Authentication Service (MAS)

- The Mobile Authentication System (MAS) as a free GSM-based service introduced in Nigeria since 2010
- MAS enables consumers to have access to a designed customer service unit to confirm whether the drug offered for sale is genuine or fake
- A simple and nevertheless successful instrument to tackle counterfeit on local markets

*Andreas Maack, Merck KGaA, Germany*

## Session 5

### EU Falsified Medicines Directive – Tamper Verification Features

#### Tamper Verification Features for Medicinal Product Packaging

- Legal Background - EU Falsified Medicines Directive
- Technical solutions for tamper evident packaging
- European Standard “Tamper verification features for medicinal product packaging”
- Current status and outlook on next steps

*Dieter Mößner, Carl Edlmann GmbH, Germany*

## Session 6

### FDA View – Anticounterfeiting Strategies

#### Updates on Supply Chain Integrity Initiatives: Office of Drug Security, Integrity and Recalls, FDA

*Dr S. Leigh Verbois, Office of Drug Security, Integrity, and Recalls, FDA, USA (via Video Conference)*

#### Short Presentations (as of 3 April 2012):

- Authenticating Medicines with an iPhone 4 App Using the Micro Surface Irregularities of Varnished and Molded Packaging Components

*Dr Fred Jordan, Co-founder and CEO, AlpVision SA*

- Complying with the new EU-Regulations of Quality Assurance and Anti-Counterfeit by RFID-tagged Pharmaceuticals

*Eldar Sultanow, CIO, XQS Service GmbH*

- Databases - No longer fit for purpose for Serialisation and Track & Trace

*Tod Urquhart, Kezzler AS*

- Track & Trace Solution based on Modified 2D Codes
- Roger Pallavicini, FO-Security*

## Speakers



### Dr Hans-Joachim Bigalke, EDQM, France

Dr Hans-Joachim Bigalke studied pharmacy at the University of Würzburg (Germany) and became a pharmacist in 1984. After his military service in the analytical department of a hospital pharmacy in Kiel (Germany), he worked in the University of Würzburg from 1985, where he obtained his PhD in analytical pharmacy in 1990. In 1990 he joined the Springer-Verlag in Heidelberg (Germany), where he continued his work in the organisation team for ‘Hagers Handbuch der Pharmazeutischen Praxis’, which he had already begun earlier as a freelancer. From 1993 to date he has been working with the Technical Secretariat of the European Pharmacopoeia, first as the Secretary of groups of experts (organic chemistry) and presently as Acting Head of the Publications and Multimedia Department of the EDQM.



### Dr Thomas Hecker, EDQM, France

Dr Thomas Hecker graduated as a pharmacist in 1994 from Martin-Luther University in Halle (Germany). He then performed his PhD studies in Pharmaceutical Chemistry at the University Leipzig. During this time he post graduated in the field of toxicology and environmental protection, after which he was a self employed pharmacist for a further four years. He joined as a GMP/GCP inspector a German agency in 2002, and is currently working as an inspector with EDQM since 2007.



### Prof Dr Ulrike Holzgrabe, University of Würzburg, Würzburg, Germany

Ulrike Holzgrabe holds a chair in Pharmaceutical Chemistry at the University of Würzburg and is a member of several national and international committees dealing with the German and European Pharmacopoeia. Thus, she is interested in modern analytical methods for quality assurance of drugs.



### Andreas Maack, Merck KGaA, Darmstadt, Germany

Andreas Maack is Head of Corporate Security at Merck and based in Darmstadt. Before he entered Merck in 2010 he worked in several functions as police officer. From there he has a range of experience in different areas of crime, criminal investigations, evidence collection, information analysis and international cooperation between different law-enforcement authorities. His task within Corporate Security include, next to all governance issues and prevention measures in the area of security, especially case and incident handling (e.g. counterfeiting investigations, product related crime) as well as security crisis management, people and information protection.



**Dieter Mößner, Carl Edelmann GmbH, Heidenheim, Germany**

Dieter Mößner is a team leader in Prepress at Edelmann Group in Heidenheim/Germany - a leading manufacturer of pharmaceutical packaging (www.edelmann.de). He is responsible for artwork services and print data communication. He is Convenor of the working group at the European Committee of Standardisation CEN (www.cen.eu) that has created the European standard EN 15823 "Braille on packaging for medicinal products". He is also Vice-chairman of the packaging standards committee at the German Standards Institute DIN (www.din.navp.de).



**Dr Stephan Schwarze, Bayer Pharma AG, Berlin, Germany**

Stephan Schwarze is Head of Counterfeit Protection Management at Bayer HealthCare Pharmaceuticals. In 2005 he started to establish and develop this function. Before he had worked in several different areas of R&D and production at increasing management levels. He is a member of EFPIA's Anti-Counterfeiting Working Group and a technical advisor to the Board of PSI and had actively worked in WHO's IMPACT Technology Subgroup. Furthermore he is engaged in the working groups related to norming activities on "Tamper Verification Features".



**Dr Bernd Renger, Chairman of the European QP Association, Germany**

Dr Bernd Renger is a member of the ECA Advisory Board and Chairman of the European QP Association. Since 2011, is running his own consultancy business. Before that he was Director of Quality Control at Vetter Pharma-Fertigung. He started his career at Hoechst AG as a research and development chemist. Since then, he has held several quality positions at Mundipharma, Altana Pharma and Baxter.



**Dr Mona Tawab, Zentrallaboratorium Deutscher Apotheker, Eschborn, Germany**

Mona Tawab studied pharmacy and did her PhD at the Johann Wolfgang Goethe University in Frankfurt. She is the deputy scientific manager and head of research and development in the Zentrallaboratorium Deutscher Apotheker (ZL). Being an independent laboratory of the German pharmacists founded to test and assure the quality of drugs, the ZL focuses on counterfeit drugs and carries out test purchases.



**Dr Hermann Thöne, Novartis Pharma AG, Basel, Switzerland**

Dr H. Thöne has graduated as PhD in Physical Chemistry at the Federal Institute of Technology (ETH) in Zürich. He is working since 25 years at Novartis Pharma AG and the predecessor company Sandoz, in various functions in Environmental Analytical Laboratories and pharmaceutical Quality Assurance.



**Dr Christian Tillmanns, Meisterernst Rechtsanwälte, Munich, Germany**

Dr Christian Tillmanns is a lawyer specialized in pharmaceutical and medical devices law. After traineeships in the legal departments of two large international pharmaceutical companies as well as in the pharmaceutical law department of an international law firm and more than 6 years practise in the law firm Kaltwasser Rechtsanwälte (specialized Advisors in pharmaceutical and health care law) he joined the Munich law firm meyer//meisterernst in 2008 and Meisterernst Rechtsanwälte in 2011. Dr Tillmanns supports companies in all questions concerning pharmaceutical law (regulatory and marketing affairs), including representing the clients in legal proceedings.

**Dr S. Leigh Verbois, CDER, FDA, USA**

S. Leigh Verbois is Acting Deputy Director of the Division of Supply Chain Integrity, in the Office of Drug Security, Integrity and Recalls, in Center for Drug Evaluation and Research's (CDER) Office of Compliance at the United States Food and Drug Administration. In this role, Dr Verbois is responsible for managing and directing strategies, activities and policies to reduce threats to the global drug supply chain through increased transparency and accountability, effective enforcement, and promotion of proactive industry vigilance and voluntary compliance.

**Social Event**

On the evening of the first conference day, you are cordially invited to a social event in the historical city of Würzburg. This is an excellent opportunity to share your experiences with colleagues from other companies in a relaxed atmosphere.



**Short Presentations by Selected Suppliers**

Vendors are invited to present new anti-counterfeiting technologies or systems in scientific short presentations (10 min presentation and 5 min discussion). Please send a short summary of your lecture to Günter Brendelberger at Concept Heidelberg (brendelberger@concept-heidelberg.de). These short presentations have to be approved by the Steering Committee of the conference (Prof Holzgrabe / Dr Schwarze) in advance.


As a prerequisite you need a regular registration for the conference or you may register for the conference exhibition.

The number of these short presentations is limited to 5.

## Conference Exhibition

---

During the two conference days, Security Technology Companies and Labelling/Packaging Component Companies are invited to exhibit their systems, products, and services in the foyer in the front of the conference room. Please contact Marion Weidemaier for further information on the opportunity to exhibit at the conference: Phone ++49(0)62 21-84 44 46, Fax ++49(0)62 21-84 44 34, e-mail: weidemaier@concept-heidelberg.de



## Organisation and Contact

---

CONCEPT HEIDELBERG  
P.O. Box 10 17 64  
69007 Heidelberg, Germany  
Phone +49 (0) 62 21/84 44-0  
Fax +49 (0) 62 21/84 44 34  
E-mail: info@concept-heidelberg.de  
www.concept-heidelberg.de

### For questions regarding content:

Dr Günter Brendelberger (Operations Director) at +49-6221/84 44 40, or per e-mail at [brendelberger@concept-heidelberg.de](mailto:brendelberger@concept-heidelberg.de).

### For questions regarding reservation, hotel, organisation etc.:

Ms Marion Weidemaier (Organisation Manager) at +49-6221/84 44 46, or per e-mail at [weidemaier@concept-heidelberg.de](mailto:weidemaier@concept-heidelberg.de).

## About CONCEPT HEIDELBERG

---

Founded in 1978, CONCEPT HEIDELBERG is the leading organiser of seminars on pharmaceutical production, quality control, quality assurance and GMP in Europe. This year more than 240 events will be organised by CONCEPT HEIDELBERG. ECA has entrusted CONCEPT HEIDELBERG with the organisation of its events.

## Würzburg – Accessibility via Frankfurt Airport

---

The transfer from Frankfurt Rhein Main Airport to Würzburg is rather convenient:

### 1. By Bus Shuttle

There will be a bus shuttle free-of-charge from Frankfurt Airport to the Novotel Hotel Würzburg on Sunday, 6 May 2012, at 20.00 h. Travelling time approx. 2 hours.

On Tuesday, 8 May 2012, buses will transfer for Frankfurt Airport directly after the end of the conference. Travelling time: approx. 2 h.

### 2. By Train

Alternatively, there is a direct 1 h 30 min train connection from Frankfurt Airport to Würzburg Main Station.



## Lufthansa is Mobility Partner for all ECA Events

---

As an ECA course or conference attendee, you will receive **up to 20% discounted travel fares** (according to availability). And as Lufthansa German Airlines offers a comprehensive global route network linking major cities around the world you will most likely be able to benefit from these special prices and conditions.


And this is how it works: Once you registered for a course or conference you will receive a link together with your registration confirmation. Opening that link will take you to the Mobility Partner Program website where you can enter a code in the "Access to Event Booking" area you will also receive. This will take you into an online booking platform that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

We look forward to welcoming at one of our next events – and we already wish you a pleasant flight!

## Easy Registration

 **Reservation Form:**  
**CONCEPT HEIDELBERG**  
P.O. Box 10 17 64  
69007 Heidelberg  
Germany

 **Reservation Form:**  
+ 49 6221 84 44 34

 **e-mail:**  
info@concept-heidelberg.de

 **Internet:**  
www.gmp-compliance.org  
www.counterfeit-conference.org

### Date

Monday, 7 May 2012, 09.00 – 18.30 h  
(Registration and coffee 08:00 – 09:00 h)  
Tuesday, 8 May 2012, 08:30 – 16:00 h

### Venue

Novotel Würzburg  
Eichstraße 2  
97070 Würzburg, Germany  
Phone ++ 49(0) 931 / 3054 – 0  
Fax ++ 49(0) 931 / 3054 - 455

### Accommodation

CONCEPT HEIDELBERG has reserved a limited number of rooms in the event hotel. You will receive a room reservation form when you have registered for the event. Please use this form for your room reservation or be sure to mention "ECA 7302" to receive the specially negotiated rate (single room per night from 6-7 May € 81,-, from 7-8 May € 91,- plus € 17,- for breakfast) for the duration of your stay. Reservation should be made directly with the hotel not later than 23 March 2012. Early reservation is recommended.

### Fees

ECA Members EUR 1,490.- per delegate plus VAT  
APIC Members EUR 1,590.- per delegate plus VAT  
(does not include ECA Membership)  
Non-ECA Members EUR 1,690.- per delegate plus VAT  
EU GMP Inspectorates EUR 845.- per delegate plus VAT  
The conference fee is payable in advance after receipt of invoice and includes conference documentation, dinner on the first day, lunch on both days and all refreshments. VAT is reclaimable.

### Registration


Via the attached reservation form, by e-mail or by fax message.  
Or you register online at [www.counterfeit-conference.org](http://www.counterfeit-conference.org).

### Conference language

The official conference language will be English.

If the bill-to-address deviates from the specification to the right, please fill out here:

Reservation Form (Please complete in full)

 +49 6221 84 44 34

**The 3rd University of Würzburg Anti-Counterfeit Conference:  
Strategies Against Falsified/Counterfeit Medicines**  
7 - 8 May 2012, Würzburg, Germany

Mr  Ms

Title, first name, surname

Company

Department

**Important: Please indicate your company's VAT ID Number**

**Please indicate the Purchase Order Number, if applicable**

Street / P.O. Box

City

Zip Code

Country

Phone / Fax

E-Mail (Please fill in)

CONCEPT HEIDELBERG  
P.O. Box 10 17 64  
Fax +49 (0) 6221/84 44 34

69007 Heidelberg  
Germany

#### General terms and conditions

If you cannot attend the conference you have two options:

1. We are happy to welcome a substitute colleague at any time.
2. If you have to cancel entirely we must charge the following processing fees: Cancellation
  - until 2 weeks prior to the conference 10 %
  - until 1 weeks prior to the conference 50 %
  - within 1 week prior to the conference 100 %.

CONCEPT HEIDELBERG reserves the right to change the materials, instructors, or speakers without notice or to cancel an event. If the event must be cancelled, registrants will be notified as soon as possible

and will receive a full refund of fees paid. CONCEPT HEIDELBERG will not be responsible for discount airfare penalties or other costs incurred due to a cancellation.

**Terms of payment:** Payable without deductions within 10 days after receipt of invoice.

**Important:** This is a binding registration and above fees are due in case of cancellation or non-appearance. If you cannot take part, you have to inform us in writing. The cancellation fee will then be calculated according to the point of time at which we receive your message. In case you do not appear at the event without having informed us, you will have to pay the full registration fee, even if you have not made the payment yet. Only after we have received your payment, you are entitled to participate in the conference (receipt of payment will not be confirmed)!